These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18980978)

  • 21. Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography.
    Furuya M; Ishikura H; Nemori R; Shibata M; Fujimoto S; Yoshiki T
    Hum Pathol; 2001 Feb; 32(2):163-8. PubMed ID: 11230703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients.
    Lutgendorf SK; DeGeest K; Dahmoush L; Farley D; Penedo F; Bender D; Goodheart M; Buekers TE; Mendez L; Krueger G; Clevenger L; Lubaroff DM; Sood AK; Cole SW
    Brain Behav Immun; 2011 Feb; 25(2):250-5. PubMed ID: 20955777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
    Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
    Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Social support, psychological distress, and natural killer cell activity in ovarian cancer.
    Lutgendorf SK; Sood AK; Anderson B; McGinn S; Maiseri H; Dao M; Sorosky JI; De Geest K; Ritchie J; Lubaroff DM
    J Clin Oncol; 2005 Oct; 23(28):7105-13. PubMed ID: 16192594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
    Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
    Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma.
    Adley BP; Gleason KJ; Yang XJ; Stack MS
    Gynecol Oncol; 2009 Feb; 112(2):319-24. PubMed ID: 18976802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China.
    Li Y; Jin X; Kang S; Wang Y; Du H; Zhang J; Guo W; Wang N; Fang S
    Gynecol Oncol; 2006 Apr; 101(1):92-6. PubMed ID: 16278009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
    Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer.
    Davis LZ; Slavich GM; Thaker PH; Goodheart MJ; Bender DP; Dahmoush L; Farley DM; Markon KE; Penedo FJ; Lubaroff DM; Cole SW; Sood AK; Lutgendorf SK
    Cancer; 2015 Oct; 121(19):3543-50. PubMed ID: 26096769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.
    Sillanpää S; Anttila M; Voutilainen K; Ropponen K; Turpeenniemi-Hujanen T; Puistola U; Tammi R; Tammi M; Sironen R; Saarikoski S; Kosma VM
    Gynecol Oncol; 2007 Feb; 104(2):296-303. PubMed ID: 17034838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
    Cardillo MR; Di Silverio F; Gentile V
    Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EphA2 overexpression is associated with angiogenesis in ovarian cancer.
    Lin YG; Han LY; Kamat AA; Merritt WM; Landen CN; Deavers MT; Fletcher MS; Urbauer DL; Kinch MS; Sood AK
    Cancer; 2007 Jan; 109(2):332-40. PubMed ID: 17154180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis.
    Jain A; Nanchahal J; Troeberg L; Green P; Brennan F
    Arthritis Rheum; 2001 Aug; 44(8):1754-60. PubMed ID: 11508425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.
    Franchi A; Santucci M; Masini E; Sardi I; Paglierani M; Gallo O
    Cancer; 2002 Nov; 95(9):1902-10. PubMed ID: 12404284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization.
    Majka S; McGuire PG; Das A
    Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):260-6. PubMed ID: 11773040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
    Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
    Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.
    Paju A; Sorsa T; Tervahartiala T; Koivunen E; Haglund C; Leminen A; Wahlström T; Salo T; Stenman UH
    Br J Cancer; 2001 May; 84(10):1363-71. PubMed ID: 11355948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between the expression of VEGF signal components and matrix metalloproteinases in ovarian tumors.
    Gershtein ES; Kushlinsky DN; Levkina NV; Tereshkina IV; Nosov VB; Laktionov KP; Adamyan LV
    Bull Exp Biol Med; 2011 Aug; 151(4):449-53. PubMed ID: 22448363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down-regulation of MT1-MMP expression suppresses tumor cell invasion in metastatic human SW626 ovarian cancer cells.
    Wu M; Xu G; Xi L; Wei J; Song A; Han Z; Zhou J; Wang S; Zhu T; Zhang A; Lu Y; Ma D
    Oncol Rep; 2006 Feb; 15(2):501-5. PubMed ID: 16391876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.